Meiji Holdings Co., Ltd. (TYO:2269)

Japan flag Japan · Delayed Price · Currency is JPY
3,739.00
+37.00 (1.00%)
Apr 28, 2026, 3:30 PM JST
8.63%
Market Cap 1.01T
Revenue (ttm) 1.16T
Net Income (ttm) 46.00B
Shares Out 271.10M
EPS (ttm) 169.74
PE Ratio 22.03
Forward PE 20.07
Dividend 105.00 (2.84%)
Ex-Dividend Date Mar 30, 2026
Volume 611,000
Average Volume 983,715
Open 3,720.00
Previous Close 3,702.00
Day's Range 3,710.00 - 3,741.00
52-Week Range 2,907.00 - 4,077.00
Beta 0.13
RSI 41.59
Earnings Date May 14, 2026

About Meiji Holdings

Meiji Holdings Co., Ltd., through its subsidiaries, engages in the manufacture and sale of dairy products, confectionery food products and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceuticals. The Food segment provides yogurt, milk, beverages, cheese, butter, margarine, cream, ice cream, prepared food, chocolate, gummy candy, sports nutrition, infant milk, liquid food, beauty products, feed, sugar, and corn sweeteners. The Pharmaceutical segment offers drugs for infectious and central... [Read more]

Industry Packaged Foods
Founded 1916
Employees 17,231
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2269
Full Company Profile

Financial Performance

In fiscal year 2025, Meiji Holdings's revenue was 1.15 trillion, an increase of 4.39% compared to the previous year's 1.11 trillion. Earnings were 50.80 billion, an increase of 0.25%.

Financial Statements

News

Meiji Holdings Earnings Call Transcript: Q2 2026

First half operating profit exceeded plan despite a slight sales shortfall, driven by strong pharmaceuticals and effective price increases. Full-year sales guidance was revised down, but profit targets remain, with ongoing structural reforms and new product launches supporting growth.

5 months ago - Transcripts

Meiji Holdings Earnings Call Transcript: Q2 2025

First-half net sales rose 4.2% year-on-year, with operating profit flat and profit attributable to owners down 3.8% due to lower extraordinary gains. Food segment faced cost pressures but expects recovery via price hikes, while pharma segment saw strong first half but faces lower second-half profit from reduced COVID vaccine demand.

1 year ago - Transcripts